JP2021535106A5 - - Google Patents
Info
- Publication number
- JP2021535106A5 JP2021535106A5 JP2021509210A JP2021509210A JP2021535106A5 JP 2021535106 A5 JP2021535106 A5 JP 2021535106A5 JP 2021509210 A JP2021509210 A JP 2021509210A JP 2021509210 A JP2021509210 A JP 2021509210A JP 2021535106 A5 JP2021535106 A5 JP 2021535106A5
- Authority
- JP
- Japan
- Prior art keywords
- gaboxadol
- pharmaceutically acceptable
- acceptable salt
- patient
- hours
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721013P | 2018-08-22 | 2018-08-22 | |
| US62/721,013 | 2018-08-22 | ||
| PCT/US2019/047673 WO2020041574A1 (en) | 2018-08-22 | 2019-08-22 | Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535106A JP2021535106A (ja) | 2021-12-16 |
| JPWO2020041574A5 JPWO2020041574A5 (https=) | 2022-08-24 |
| JP2021535106A5 true JP2021535106A5 (https=) | 2022-08-24 |
Family
ID=69591079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509210A Withdrawn JP2021535106A (ja) | 2018-08-22 | 2019-08-22 | 消化管障害および喘息の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210177805A1 (https=) |
| EP (1) | EP3823619A4 (https=) |
| JP (1) | JP2021535106A (https=) |
| KR (1) | KR20210049855A (https=) |
| CN (1) | CN112888437A (https=) |
| AU (1) | AU2019326539A1 (https=) |
| CA (1) | CA3110218A1 (https=) |
| IL (1) | IL280859A (https=) |
| MX (1) | MX2021002113A (https=) |
| WO (1) | WO2020041574A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| KR20220157426A (ko) * | 2020-03-25 | 2022-11-29 | 세이지 테라퓨틱스, 인크. | 호흡기 병태의 치료를 위한 작용제의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| AU4307800A (en) * | 1999-04-30 | 2000-11-17 | Merab Lomia | New indication for use of antiepileptic agents and medicines |
| WO2006102093A1 (en) * | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| IL256912B2 (en) * | 2015-07-17 | 2024-01-01 | Ovid Therapeutics Inc | Methods of treating developmental disorders with gaboxadol |
-
2019
- 2019-08-22 CN CN201980069028.1A patent/CN112888437A/zh active Pending
- 2019-08-22 WO PCT/US2019/047673 patent/WO2020041574A1/en not_active Ceased
- 2019-08-22 MX MX2021002113A patent/MX2021002113A/es unknown
- 2019-08-22 JP JP2021509210A patent/JP2021535106A/ja not_active Withdrawn
- 2019-08-22 KR KR1020217008438A patent/KR20210049855A/ko not_active Withdrawn
- 2019-08-22 AU AU2019326539A patent/AU2019326539A1/en not_active Abandoned
- 2019-08-22 US US17/270,377 patent/US20210177805A1/en not_active Abandoned
- 2019-08-22 CA CA3110218A patent/CA3110218A1/en active Pending
- 2019-08-22 EP EP19852671.7A patent/EP3823619A4/en not_active Withdrawn
-
2021
- 2021-02-14 IL IL280859A patent/IL280859A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9220696B2 (en) | Pharmaceutical combinations for treatment of specific cancers | |
| JP6145778B2 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| CN101848708A (zh) | 皮质类固醇用于治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻 | |
| WO2018062134A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2021535106A5 (https=) | ||
| KR102843222B1 (ko) | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 | |
| CA3144374A1 (en) | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors | |
| CN113893256A (zh) | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 | |
| US20220241386A1 (en) | Micronutrient combination to reduce blood pressure | |
| CN108904484A (zh) | 一种没食子酸乙酯的用途 | |
| JPWO2020041574A5 (https=) | ||
| JP2024506041A (ja) | 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド | |
| US20210186950A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| CA2538202C (en) | Use of ciclesonide for the treatment of inflammatory bowel diseases | |
| KR102916453B1 (ko) | 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도 | |
| US20240216384A1 (en) | Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound | |
| US6545044B2 (en) | Compositions of matter containing L-glutamine and pyridoxal-alpha-ketoglutarate | |
| US7842702B2 (en) | Treatment for irritable bowel syndrome | |
| WO2021081081A1 (en) | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | |
| HK40059774A (en) | Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer | |
| WO2007010946A1 (ja) | 滑膜細胞増殖抑制剤 | |
| EP4720090A1 (en) | Protective agent against endothelial dysfunction | |
| WO2003059355A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| Del Castillo et al. | A PHASE II RANDOMIZED PHARMACOKINETIC (PK) STUDY OF TACROLIMUS (TAC)-EVEROLIMUS (EVL) COMBINATION FOR KIDNEY TRANSPLANTATION (KT): 449 | |
| CN1682715A (zh) | 一种抗缺氧药物组合物 |